Richards, Merrill & Peterson’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.45M Buy
1,255
+99
+9% +$117K 0.44% 57
2026
Q2
$1.39M Buy
1,156
+115
+11% +$118K 0.44% 59
2026
Q1
$958K Buy
1,041
+25
+2% +$25.3K 0.35% 73
2025
Q4
$1.09M Hold
1,016
– – 0.42% 64
2025
Q3
$775K Buy
1,016
+249
+32% +$185K 0.33% 87
2025
Q2
$598K Buy
767
+156
+26% +$121K 0.28% 90
2025
Q1
$505K Buy
611
+43
+8% +$35.8K 0.26% 90
2024
Q4
$438K Buy
+568
New +$470K 0.23% 100

Other funds holding LLY

Richards, Merrill & Peterson's LLY Position: Q3 2026 in Review

Richards, Merrill & Peterson increased its Eli Lilly (LLY) stake by 8.6% in Q3 2026, buying an estimated $117K and bringing the position to 1,255 shares worth $1.45M. The position accounts for 0.44% of the portfolio, ranked #57.

Richards, Merrill & Peterson first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 3,244 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Richards, Merrill & Peterson held 1,255 shares of Eli Lilly worth $1.45M as of Q3 2026.
  • Richards, Merrill & Peterson bought 99 Eli Lilly shares in Q3 2026, an estimated $117K.
  • Eli Lilly made up 0.44% of Richards, Merrill & Peterson's portfolio in Q3 2026, its #57 holding.
  • Richards, Merrill & Peterson first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 3,244 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Richards, Merrill & Peterson's 13F filing for Q3 2026, filed 19 Oct 2026.